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Introduction
In this project, we have proposed to test the central hypotheses that the Bini gene is required for normal development of the prostate and to restrain the initiation or progression of prostate cancer. The foundations of this central hypothesis were twofold. First, Bini encodes an adapter protein that inhibits the transforming activity of the Myc oncoprotein, the activation of which drives a large fraction of prostate cancers (1) (2) (3) (4) (5) (6) (7) (8) . A large body of evidence supports the likelihood that Bini can function to promote differentiation, to facilitate stress signaling, and to restrain malignant development (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) . Furthermore, several lines of evidence argue that in certain transformed cell settings Bin1 can facilitate a p53-independent mechanism cell suicide that can be triggered by Myc and other proapoptotic stimuli (14, 15) . Loss of Bin1 may therefore relieve blocks to malignant development that involves a mechanism of differentiation and cell death. The second foundation to the central hypothesis tested in this project is that we have found Bini to be attenuated very frequently in human prostate cancers (12, 16 ) (McDonnell, T.J., Do, K.-A., Troncoso, P., Wang, X., Bueso-Ramos, C., Coombes, K., Brisbay, S., Lopez, R., Prendergast, G.C., and Logothetis, C. Application of data modeling strategies to prostate cancer tissue microarray: an analysis of selected cell cycle and cell death regulatory proteins. Manuscript submitted.) Thus, the restraint provided by Bin1 to the development of prostate malignancy may be relieved at some point during tumor development, possibly relieving the 'death penalty' which is associated with Myc activation in this setting (19) .
While an unambiguous function for Bin1 has yet to be defined, when taken as a whole the literature suggests that this gene encodes a scaffold that acts to integrate signaling and trafficking processes in cells, perhaps crucial in cells under stress. With regard to cancer development, a key question is whether the common attenuation of Bin1 expression in cancers is derivative or causative with regard to tumor initiation or progression. This key question can be addressed using knockout mouse models, where a causative role can be established by demonstrating that gene ablation can promote one or both of these processes. In this project, a conditional knockout model based on well-established cre-lox technology is being used. Briefly, we constructed a mouse strain in which Bin1 function can be ablated specifically in the prostate at the age of sexual maturation (-7 wks), by an allelic deletion that is generated by prostate-specific induction of Cre recombinase. Through this strategy, we can monitor the consequences of Bin1 loss at early times on androgen-driven development and homeostasis of the prostate (Aim 1). If Bin1 loss is sufficient to promote tumor formation, then at later times one would expect an elevation in the formation of preneoplastic or neoplastic lesions (Aim 1). If, alternately, Bin1 loss does not promote tumor initiation, but is instead sufficient to drive tumor progression, then one would expect an increase in the progression of pre-neoplastic or neoplastic lesions that are initiated by a separate event, in this case, by Myc activation (Aim 2). These are distinct aims, because it is readily conceivable that while Bin1 may have no role in development, homeostasis, or tumor initiation, it may be still have a critical role in limiting tumor progression (e.g. by stanching survival, motility, angiogenesis, or immune rejection after the tumor has developed). Indeed, preliminary studies suggest that Bin1 has a predominant role in limiting cancer at the level of progression, by acting as a negative modifier of survival but also of immune evasion of neoplastically transformed cells (20).
Body
Previous progress. Year 1 of this project was consumed mainly by performing breeding required to generate the desired experimental strains. In that phase of the work, as described in last year's progress report, we confirmed three important expectations of the system (briefly summarized here). First, we confirmed that the 'foxed' allele of Bin1 that had been generated could phenocopy the wild-type allele (before Cre-mediated deletion). Second, we confirmed was that the 'foxed' allele could successfully convert to the 'floxA' allele in vivo, in mice where the Cre gene was coexpressed. Lastly, we confirmed was that the floxA allele was in fact a functional knockout allele for Bin1. During Year 1 we also generated mosaic offspring in which different tissues displayed mixed KO/flox and KO/floxA genotypes. As discussed further below, these mosaic mice have turned out to be very important because they have provided a way around an unexpected pitfall in the initial experimental model that emerged in Year 2.
Emergence of a pitfall and development of an alternate strategy in Year 2. Last year we achieved Task I of Objective I and Tasks I and II of Objective II, namely, to generate mice of the desired genotypes. However, in Year 2 we learned that the tetregulated Cre transgene used for prostate-specific Bin1 knockout was in fact defective in operation. In the PB-cre transgenic mouse strain employed, Cre expression was directed specifically to prostate cells under control of the tet regulator doxocycline (added to drinking water at the desired time of induction). Unfortunately, we were unable to achieve the desired Bin1 knockout due to a lack of Cre induction in the prostates of the PB-cre;KO/+ and PB-cre;KO/flox strains and also the PB-cre;PBmyc;KO/+ and PB-cre;PB-myc;KO/flox strains that had been generated. Despite efforts to resolve this issue by several approaches (increased doxycycline adminstration, different routes of administration, using different litters of mice, using mice of different ages), we were not able to achieve Cre induction, as measured by RT-PCR, nor Bin1 knockout (as would be expected due to the lack of Cre induction). It remains unclear whether this problem derives from the mixed strain background of the strains that were generated, which differ from the original PB-cre strain, or from some other problem. In any case, this problem prevented us from accomplishing the remaining Tasks in Objectives I and II as originally proposed.
Construction of mosaic Bin1 knockout mice.
The mosaic KO/flox strains that we created in Year I as a side project offered an alternate strategy to complete this proposal. Briefly, we generated KO/flox mosaic mice that are composed of a mixture of Bini null and Bin1 heterozygous cells throughout the animal. These animals were derived from crossing an Ella-cre transgene onto the Bin1 KO/flox genotype. The Ella promoter (derived from the Ell gene of adenovirus) is known to be expressed only during El-E4 of mouse development (21). Thus, in the Ella-cre;KO/flox mice the transient activation of Cre resulted in Bin1 knockout (i.e. generation of a KO/floxA genotype) in some cells but not all cells of the resultant mouse. The generation of these mice has been described in a manuscript that is not yet submitted but that is included for reference in the Appendix. Consistent with previous reports of the effects of Ella-cre on 'foxed' gene recombination (21), we observed that different Ella-cre;KO/flox mice have different levels of Bin1 gene knockout throughout various tissues, but that within each individual mouse the percent knockout across tissues is fairly uniform. Figure 1 presents the flox gene organization and the PCR primers used for genotyping the normal and floxed allele of Bin1. Figure 2 presents a comparison of the genotypes of mosaic and 'straight' knockout animals (left panel) and the tissue uniformity in the genotypes from highly or weakly mosaic individuals that are generated. Ella-cre;Binl KO/floxA" c animals was subjected to multiplex PCR using primers presented in Figure 1 . One animal exhibits a mosaic genotype in the toe clip tissues whereas the second exhibits a nearcomplete knockout genotype. Right panel, PCR performed on tissues from two different Ella-cre;Binl KO/flox~mIsa'c animals illustrates that differences in overall degree of mosaicism are similar between tissues of the same individuals.
We have exploited these mosaic Bin1 knockout mice as an alternate strategy to address the central questions of this proposal, namely, whether Bin1 loss is sufficient on its own to drive the formation of premalignant and malignant prostate lesions, and/or whether Bin1 loss will cooperate with Myc to drive progression of premalignant lesions that are initated by Myc.
Progress in the alternate experimental strategy. Following this alternate strategy, in
Year 2 we completed the generation of the new strains of mice that were desired (equivalent to Task I, Objective I and Tasks I and II, Objective II). Briefly, using an Ellacre-based strategy, we completed the generation of cohorts of mosaic mice that are Ella-cre;Binl KO/floxAmic or Ella-cre;PB-myc;Binl KO/floxAmwsaic and have begun to monitor them for formation of premalignant lesions or malignant tumor formation.
Recent advances in our laboratory argue that Bin1 loss is insufficient to initate cancer Recent advances in our laboratory argue that Bin1 loss is insufficient to initate cancer but sufficient to promote tumor progression (20, 22) (preprints of these papers in press are provided in the Appendix). Therefore, we predict that Bin1 loss will not cause prostate cancer unless Myc is also activated in the prostate.
Key Research Accomplishments
1.
Discovery of a pitfall in the use of a PB-cre transgene to elicit prostate-specific knockout of a floxed Bin1 allele in a mixed PB-cre;Binl KO/flox strain.
2. Generation of Ella-cre;Binl KO/flox and Ella-cre;PB-myc;Binl KO/flox mouse strains that are mosaic for Bini knockout.
Reportable Outcomes
None this period.
Conclusions
A pitfall that emerged in Year 2 of the project was circumvented by the use of mosaic Bin1 knockout mice that were generated as a side-project in Year 1. By this alternate strategy, new strains of mice were created that have the capacity to address the central questions of the proposal. Studies will proceed to assess the effects of Bin1 loss on prostate homeostasis and the incidence of preneoplastic or neoplastic lesions in the prostate. Immune cells create a complex cytokine environment that promotes isoforms is important for cancer suppression; however, there is little cancer cell survival, angiogenesis, invasion and metastasis 1 .To survive information about the relevant effector pathways or about the prein this environment, however, cancer cells expressing recognizable cise pathophysiological consequences of attenuating the expression of tumor antigens must evolve strategies to thwart immune detection nuclear isoforms, as occurs often in human malignancies 3 ,5-a. and destruction 2 . Immune escape is thus a hallmark of cancer pro-IDO is emerging as an important immunoregulatory enzyme. gression, but its underlying molecular genetic basis remains poorly It catalyzes the initial rate-limiting step in tryptophan catabolism, understood. The interplay between immune escape and other hall-which leads to the biosynthesis of nicotinamide adenine dinucleotide marks of malignant conversion, such as invasion and metastasis, is [AU: Addition of'adenine' correct?]. By depleting tryptophan from similarly obscure. Aggressive and disseminated cancers can be eradi-local microenvironments, IDO can block activation of T lymphocated by an appropriately activated immune system, arguing that cytes, which are particularly sensitive to loss of this essential amino overcoming immune escape might have broad therapeutic impact, acid","s. Notably, IDO is needed to prevent T cell-mediated rejection but this expectation has yet to be realized. Small-molecule drugs are of allogenic concepti 1 9 . IDO is overexpressed in many cancers, where of particular interest because of their relative advantages compared it has been implicated in immune escape 20 , 21 . But its importance to to biological agents in terms of production, delivery and cost. Yet cancer progression and therapy has yet to be gauged fully. Here we few small molecules for stimulating antitumor immunity have been identify a mechanism for IDO elevation in cancer, and we show how described.
pharmacological inhibitors of IDO can be used in combination with Studies of the BAR adapter-encoding gene Bin] (also known as cytotoxic chemotherapeutic agents to elicit regression of established Amphiphysin2) indicate that it functions in cancer suppression 3 -9 . tumors. (Fig. ic) . The significant difference in tumorigenicity neutrophils 2 3 . Carrageenan treatment enhanced tumor formation by between Binl-'-and Bini'l-cells (P < 0.0001) could not be explained Bin)l+-cells but not by Binl-P-cells (Fig. if) , consistent with the idea by increased intrinsic cell proliferation, because Bini+-cells were no that cross-priming is involved in the antitumor immune response. In less aggressive at forming tumors than Bin 1 -/-cells in T cell-deficient, summary, we conclude that Binl suppresses tumor formation through a athymic nude mice (Fig. ld) or in syngeneic mice depleted of both CD4+ cell-extrinsic, immune-based mechanism that appears to be dependent and CD8+ T cells (Fig. le) . Because tumor cells present antigens in part on both T cells and APCs. Fig. transcription were abolished by introduction of a 'super-repressor' 2c). Transcription assays in human HeLa cells showed that attenuation mutant of I KB, which prevents NF-KB activation, as well as by a domiof BinI by either siRNA or dominant inhibitory strategies increased basal nant negative STATI mutant, which prevents STAT1 activation (Fig. 2f) . and IFN-7-induced activity of the Indo promoter (Fig. 2d) . Similarly, Taken together, these results indicate that Indo expression is under the Bin1 deletion elevated basal and IFN-7-induced activity of the Indo pro-genetic control of Bin] at the level of NF-jB-and STAT1-dependent moter in MRKECs, and these effects were reversed by ectopic expres-transcription. , ARTICLES
. Tumor-bearing MMTV-Neu mice were treated with either 1MT (+IMT) or placebo (-1MT) in combination with the cytotoxic drugs and molecular therapeutic agents indicated (at the doses indicated). We scored tumor volumes just before and 2 weeks after initiation of therapy. Fold changes in tumor volumes were determined and the means are presented for each group. i.v., intravenous; i.p., intraperitoneal; p.o., per os (orally) lAU: OK as editedfl: qdxl 1, [AU: Please define ndxl 1.1 [AU: P is between which grouns? Please also define FTI and ensure that structure is available, otherwise must be removed.1 the delivery method used (subcutaneous time-release pellets) could elicit decrease in tumor volume within 2 weeks of initiating therapy, whereas maternal immune rejection of allogeneic but not syngeneic concepti paclitaxel delivered at near the maximum-tolerated dose (MTD) only (Supplementary Fig. 1 online), indicating sufficient systemic expo-slightly retarded tumor growth (Fig. 4a ). Histopathological analysis of sure of 1MT to achieve biological activity. In tumor-bearing animals, tumor sections from 1MT + paclitaxel-treated mice offered evidence 1MT inhibited the growth of Binl-l-tumors in syngeneic hosts but of increased tumor-cell death (Fig. 4b ). Immune depletion of CD4' not in nude hosts (Fig. 3a) . Moreover, immune depletion of CD4+ T T cells limited tumor growth relative to control tumors during the cells from syngeneic animals abolished the ability of 1MT to suppress experiment but, as expected, it abolished the ability of 1MT + paclitaxel Bin1-l-tumor growth (Fig. 3b ). 1MT does not seem to be directly cyto-treatment to elicit tumor regression (Fig. 4c ). This effect correlated with toxic or growth inhibitory, as it did not affect tumor growth in nude a reduction in tumor-cell death as evidenced by histological analysis of or immune-depleted syngeneic mice, nor were cytotoxicity or growth tumor sections (Fig. 4d) . inhibition observed when MRKECs were treated with 1MT in vitro (data It is unlikely that a drug-drug interaction simply caused an increase not shown). We conclude that IDO elevation is a critical mediator of in the effective dose of paclitaxel, which was administered at near the immune escape caused by Bin I loss. MTD 2 8 [AU: Please spell out.], because we did not observe characteristic neuropathies that would be expected to occur if 1MT had increased IDO inhibitors potentiate cancer chemotherapy the effective dose (data not shown). Furthermore, this interpretation
We next investigated whether IDO is critical for tumor survival in does not explain the effectiveness of combining 1MT with other drugs MMTV-Neu mice, a well-accepted transgenic mouse model of breast cleared by different mechanisms. We ruled out the trivial possibility that cancer, which, like human malignant breast cancers, shows attenuation high doses of a tryptophan-like compound were sufficient by showing of Bin 1 expression ( Supplementary Fig. 2 online). MMTV-Neu mice that DL-tryptophan [AU: Is DL correct?] was ineffective when subbearing autochthonous tumors were randomly enrolled into control and stituted for 1MT in the regimen (data not shown). Lastly, we further treatment groups when tumors reached a diameter of 5-10 mm. 1MT confirmed the requirement for T cell-dependent immunity by showing was administered as in the MRKEC tumor graft setting described above, in a tumor graft model, using an MMTV-Neu-derived tumor cell line, In some trials, we combined lMT with paclitaxel, a chemotherapeutic that IMT showed effects only when the tumors were established in agent used for breast cancer treatment, based on reports that taxanes immunocompetent syngenic mice and was ineffectual in T cell-defipromote T-cell infiltration of tumors
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. By itself, IMT retarded but did cient athymic nude mice ( Supplementary Fig. 3 online) . not arrest outgrowth ofautochthonous tumors (Fig. 4a) . Combinations
We next evaluated the effects of combining 1MT with other cytotoxic with either IFN-y or interleukin (IL)-12 did not accentuate the effect of drugs with diverse mechanisms of action that are used to treat breast IMT (data not shown), arguing that IDO inhibition could not compro-cancer (Table 1 ). Among the agents tested were the DNA alkylating mise the survival of established tumor cells, even when combined with drugs cisplatin and cyclophosphamide, the topoisomerase inhibitor immune stimulatory cytokines.
doxorubicin (adriamycin), the antimetabolites 5-fluorouracil and In marked contrast, combining I MT with various cytotoxic agents led methotrexate, and the antimitotic agent vinblastine. We also tested to tumor regressions under conditions where single agents were inef-several molecular targeted agents, including a farnesyl transferase fectual. Combining 1MT with paclitaxel resulted, on average, in a 30% inhibitor (FTI; L-744,832), the mTOR pathway inhibitor rapamycin, and the angiogenesis inhibitor tetrathiomolybdate. 1MT cooperated combinatorial efficacy was fully retained when the MTH-trp dose was with cisplatin, cyclophosphamide and doxorubicin to elicit mean tumor reduced twofold and partly reduced when the dose was reduced fourregressions that differed significantly (P < 0.05) from the impact of fold (data not shown) [AU: Fold reductions in this sentence unclear single-agent therapy (Table 1) . Mean tumor regression was also pro-Please restate using percentage or fraction.l. The ability of MTHduced in combination with FTI; however, as a result of the growth trp to effectively combine with paclitaxel in a similar manner as 1MT suppression produced by FTI alone, the differential with the combina-strengthens the interpretation that the basis for this cooperativity is tion treatment did not meet the threshold for assigning significance through IDO inhibition.
(P > 0.05; A new inhibitor of IDO with antitumor activity Here we address this gap in knowledge by defining a genetic mechanism
The observations described above are consistent with the presumptive that restricts the ability of cancer cells to escape T cell-dependent antispecificity of 1 MT for IDO; however, we wished to address off-target tumor immunity. Using a mouse knockout model, we have shown that concerns by examining the ability of a structurally distinct inhibitor of Bin) can restrain immune escape of oncogenically transformed cells IDO to elicit tumor regression in combination with paclitaxel. Toward by restricting expression of IDO, an immunoregulatory enzyme that is this end, we screened for bioactive inhibitors among commercially avail-widely elevated in human cancer 2 1 . Bin I is likewise widely attenuated able indoleamine-containing compounds, using a purified recombinant or mis-spliced in cancers of the breast, prostate, colon, brain and other human IDO enzyme for in vitro assays and a human INDO cDNA for organs . expression in cell-based assays. Both assays used a colorimetric method The finding that IDO is under negative genetic control by Bin1 offers to quantify the production of kyneurinine, the product of reaction mechanistic insight into how immune escape may be enabled during catalyzed by IDO 29 . Several compounds were identified that showed cancer progression. inhibition constants against recombinant human IDO that were within Translational studies prompted by our findings have led us to identify about two-to threefold of I MT (Ki = 34.2 KM). One active compound a new strategy for cancer treatment that combines IDO inhibitor-based was methyl-thiohydantoin-tryptophan (MTH-trp), which biochemical immunomodulation with cytotoxic chemotherapy. Although gene ablaanalyses showed to be a competitive inhibitor with Ki = 11.6 gM (Fig.  5a ). Cell-based screens were performed after transient expression of human INDO cDNA in COS-1 monkey cells. As a counterscreen for a [IMT(PM) selectivity, the inhibitory activity of the compounds against the struc-0 turally distinct liver enzyme TDO2 was also determined. MTH-trp was I00 -20-fold more potent than 1MT in the cell-based assay (Fig. 5b) . Two other thiohydantoin derivatives of tryptophan with lower potency than MTH-trp were also identified (data not shown), confirming the IDOinhibitory nature of this structural class and suggesting that the thiohy-0 wo i0c tli as dantoin sidechain is probably a mimetic of the amino acid backbone in Tm (Wi) tryptophan (Fig. 5a ). Pilot pharmacology experiments have indicated that MTH-trp is more soluble in aqueous solution than 1MT but is also MTH-trp (•M) more rapidly cleared from serum; both compounds were found to be 0 orally bioavailable ( Supplementary Fig. 4 online) . so Using the same formulation, route of delivery and dose used previa 100 ously to administer 1 MT, we observed that combining MTH-trp with "Ol paclitaxel produced regression of tumors as well or better than 1MT Ki =11.4 pM (Fig. 6a) . At the same 2-week endpoint, autochthonous tumors sub-0 b i6c 14 -. jected to the combination therapy regressed, on average, 45% relative Tm (pM) to the starting tumor volume. One mouse in the trial showed complete tumor regression. Histological examination of tumor sections confirmed evidence of tumor-cell death elicited by the combination b 100 therapy, as expected (Fig. 6b) . Like 1MT, MTH-trp administered by .1 itself retarded tumor outgrowth but did not promote regression. In7.IDO÷1MT 44 ,4 5 , a phenomenon that can be explained by IDO overexpression in tumors 21 .IDO catalyzes the initial step in tryptophan catabolism that leads to biosynthesis of nicotinamide adenine dinucleotide.
But IDO does not catabolize dietary tryptophan, and because mammals salvage rather than synthesize nicotinamide adenine dinucleotide, the biological role of the enzyme was obscure until it was shown IA1:
Our style precludes mention of specific author names.l that localtion studies are needed to fully validate IDO as a therapeutic target, the ized tryptophan catabolism forms the basis for a unique mechanism chemical genetics strategy used here offers an initial line of support. of establishing peripheral tolerance' 9 34 . In may be relevant. Because of a lack of mechanistic understanding, most future work, it will be important to distinguish these possibilities, for studies of Bin 1 adapter proteins have ignored evidence of nuclear local-example, by determining whether combinatorial efficacy is retained ization of the ubiquitous isoforms , despite an established prec-against drug-resistant tumor cells and whether the cytotoxic drugs that edent for nuclear localization of other'endocytotic-like' proteins (e.g., are effective in combination with IDO inhibition have similar effects on epsin and CtBP, also known as BARs write out BAR.). Nuclear localization is also intriguing given intrinOur findings are consistent with the interpretation that IDO activity sic transcriptional repression activity associated with the Bin 1 BAR in tumor cells is the relevant target for inhibition; however, they are domain 4 (M. Huang, P.S.D. and G.C.P., unpublished data). Indeed, a not incompatible with the possible involvement of stromal APCs, in recent study of the BAR adapter protein APPL reinforces this concept by which IDO can also be highly expressed (e.g., as in the draining lymph showing not only its nuclear trafficking function but also its association nodes of breast tumors 46 ). Thus, it is possible that IDO inhibitors may with the chromatin remodeling complex NuRD/Mi-2 that represses act in part by blocking an immune-tolerizing activity of APCs that are transcription1 6 . In summary, effects on trafficking and/or transcrip-located at distal sites. From a therapeutic standpoint, the possibility that tional repression by Bin) may be relevant to its regulation of IDO.
IDO maybe a stromal target increases its appeal because of the reduced This study extends the evidence that BinI limits cancer pathophysi-likelihood of selecting for drug resistance (relative to genetically plastic ology and Myc oncogenicity3- . Earlier work on cell-intrinsic tumor cells), and because of the increased range of tumors that might suppressor roles of Bin I are expanded here by the identification of a be treated even in the absence of IDO overexpression. In closing, this cell-extrinsic suppressor role that involves restraining a protoleragenic study proposes IDO as an attractive and tractable target for the developmechanism that tumor cells can exploit to escape antitumor immunity. ment of small-molecule immunomodulatory drugs to safely leverage These cell-intrinsic and extrinsic suppressor roles might be intertwined the efficacy of standard chemotherapeutic agents. given the complex involvement of the immune stromal environment in cancer pathophysiology. Myc overexpression is associated with major METHODS histocompatibility complex (MHC) class I downregulation in neu-Drugs and chemical compounds. We purchased drugs as clinical formulations 6 VOLUME 1 II NUMBER 3 I MARCH 2005 NATURE MEDICINE ARTICLES or formulated them as described in Supplementary Methods online. For in vitro mice were injected one time per week up to the experimental endpoint. studies, 1MT (Sigma) and MTH-trp (Sigma) were formulated in dimethyl sulfoxide (DMSO), including 0.1 N HC1 for the less soluble compound 1MT. For in IDO enzyme assays and inhibitor screens. We purified recombinant human vivo studies, 1MT and MTH-trp were formulated in 2-week time-release pellets his 6 -IDO from E. coli strain BL2IDE3pLys and used it in enzymatic reactions (Innovative Research).
essentially as described 29 . The biochemical and cell-based inhibitor screening assays that were used to identify new IDO inhibitors were performed in a 96-well Tissueculture. We obtained and cultured primary skin keratinocytes from E18.5 plate format, as described in detail in Supplementary Methods online. days post-coitus IAU, OK for.dK?l mouse embryos on a mixed 129sv/BL6 background' 2 , essentially as described 47 . Transformed cell populations, referred to Accession numbers. The GenBank accession numbers for the human IDO Northern and western blot analyses. We used standard methods as described in ACKNOWLEDGMENTS Supplementary Methods online. We generated a mouse monoclonal antibody We thank J. Baker for providing assistance in generating primary keratinocytes recognizing the mouse and human IDO proteins (clone 10.1; UBI) essentially as from late-stage embyros and for characterizing transgene expression in described 4 interactins withe mathe tsrohiphtional reprssiony chromx generated as descbed for analysis of cytochrome C. 39 Procedures for analyinteractions with the transcriptional repression complex sis of Binl protins wth monoclonal antibody 2F1 1 have been described. 40 NuRD/Mi-2. 29 Thus, some BAR adapter proteins may link traffickMethods recommnded by the vendors were used to analyze c-Myc, H-Ras, ing processes to transcription or other nuclear events in a manner TRADE, caspasc-3, and caspase-9 (Santa Cruz Biochemicals); IKB, phosthat yet to be fully appreciated. In this study, we exploited a recently pho-hB, a~nelBid (Cell Signaling); PARP (Chemicon); and cytochrome C developed knockout mouse model1 6 to probe the hypothesized (Phrfsunen). anti-proliferative role of Bin] in c-myc-transformed cells.
Eidocytosis Assay. Endocytic uptake of FITC-conjugated transferrin (Molecular Probes) was assessed in MR MEFs by flow cytometry 30 min
MATEILS AND METHODS
alfer addition to cells in growth media as described previously.' 6 EMSA Assay. Electrophoretic mobility shift assay for NF-icB was conCell Culture. Mixed 129sv/BL6 mice heterozygous for the Bin]
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ne
. ducted using nuclear extracts prepared 4 hr after treatment of ER MEFs were mated to heterozygous p 5 3 null mice (Jackson Laboraroies) andoff-with 100 ng/ml TNF-a, essentially as described. 4 1 The oligonucleotide used spring from this mating were interbred to generate a mbyspr• t•of•t were for the probe encoded the sequence CATGAGTTGAGGGGACTTTCheterozygous or homozygous for each gene. p53 is a key su~ppressr of c-myc, CCAGGC. so to assess the contributions of Binl as a supptessor of e-su we wished to Tumor Formation Assay. 1 x 106 cells suspended in 200 PI of DMEM focus solely on the p53-independent effects of BinI. Primary mouse embryo were injected into Fl syngeneic hosts produced by crossing 129S1/SvImJ fibroblasts (MEFs) cultured from 13.5 dpc embryos that were p53"-1 and and C57BL/6J breeders (Jackson Laboratories). Tumor growth was monitored either Bin]*'-or Binl"/" were tranfsormed with • ncogenes in vitro as by caliper measurements. Necropsy was performed at the two week endpoint described.1 6 Cells with a heterozygous genoype were used to control for the and final tumor measurements and wet weight were recorded. Tumor volumes neo cassette used for gene replacent at the murine Bin) locus.' 6 were calculated using the formula width 2 x length x 0.52. Statistical analysis Myc+Ras-transformed MEF popations. reerred to as MR MEFs or MR was performed using Prism4 software. cells, were generated either by expansion of clonal foci produced by transfection of the vectors pLTR-Hm (deregulated human c-myc) and pT22 R ULTS (human c-H-rasV12),j' or by infection of cells with ecotropic retroviruses expressing these gears (se below). SV40 large T+Ras-transformed MEFs, Bin) Deletion Promotes Growth and Tumor Formation in c-my+mras-referred to as TR MEFs or T, cells below, were generated by expansion of Transformed Cells. Transformation of primary rodent cells by c-myc requires clonal foci produced by pueoCMV-Tag (SV40 T antigen under the control a collaborating oncogene such as activated ras. Therefore, to examine the of the CMV enhanier/promoter) and pT223°). TR MEFs have a wild-type effects of Bin) deletion on c-myc oncogenicity we compared the phenotype p53 genotype, 6ut p53 is inactivated in these cell populations due to inter-of primary mouse embryo fibroblasts (MEFs) that were corransformed with action with lag T antigen. MEFs transformed by the adenovirus EIA plasmids encoding human c-myc and activated H-rasVl2, termed below MR region (encoding the 9S, 12S, and 13S EIA oncoproteins) plus activated MEFs or MR cells. Our experience with MEFs is that they are refractory to H-RasV12, referred to as ER MEFs or ER cells, have been described previtransformation by c-myc+ras if the p53 pathway is intact, so MR MEFs ously.' 5 For retroviral gene transduction, the plasmid vector MSCV-pac 33 generated in this study were derived from a p534-background (i.e., Bin I /'-was modified to express human c-Myc, H-RasV12, or Bin1[-10] or p53"/ versus Binlf/ p535' MR MEFs were compared; heterozygous cells Binr[-10-13] cDNAs3°' 34 via the production of helper-free viruses. To were used to control for the neo cassette used for gene replacement at the generate retroviruses, 293 cell-derived Phoenix cells 35 plated the previous Bin) locus ' 6 ). This design was also desirable because it allowed an assessment day at 2 x 106 per 10 cm dish were transfected transiently with plasmids mixed of the p53-independent effects of Bin] suggested by previous experiments. 5" 3 with Lipofectamine 2000 as recommended by the vendor (Invitrogen). We also generated additional transformed MEF populations on a wild-type High titer retrovirus stocks were prepared for use essentially as described.35,36 p53 gbackground using the SV40 large T antigen plus activated H-ms To obtain cell populations doubly infected with c-Myc and H-Ras virus, (termed TR MEFs or TR cells). Transformed MEF populations were derived c-Myc retroviral infection was first carried out after which the cells were from individual cell foci that arose from monolayer cultures of primary cells washed with media and H-Ras retroviral infection was performed.
after oncogene transfection and also, in the case of MR MEFs, from cells Puromvcin at 2 g/nml was applied 48 hours after infection to remove uninfected infected with ecotropic recombinant retroviruses. We observed increased (Fig. 2B) . Flow cytometry Figure 2 . Effect of Bin I loss on cell morphology and anchorage-independent proliferation. (A) s ence in the apoptotic susceptibility of Morphology. Cells were photographed at 10Ox magnification using phase optics. (B) Cell prolif-Bi nder anchorage-independent conditions oration. Standard SRB assay was conducted on plastic tissue culture dishes or dishes coated with (data ot shown), consistent with evidence that p53 the nonadherent substratum polyHEMA as described.
37 1 x 106 cells were seeded into growth isuption and ras gactivation greatly reduce sensitivity media in triplicate and counted 72 hr later. The experiment was performed twice.
c-my)c-mediated apoptosis.' Thus, we attribute the superior outgrowth of the Bin]--p53-1-MR MEFs under these conitions to enhanced proliferation. Binl loss conferred a simiranh orage-independent growth advantage to TR MEFs (Fig. 2B) .
towev his effect could be derivative of a benefit to c-Myc-mediated "" ftion, because T antigen requires c-myc activity to drive cell prolif-
TR MEF e on. 42 The growth inhibitory effects of Bin) could not be mediated by tMhe p53 or Rb pathways, because p53 was inactivated by targeted gene deletion or T antigen binding in the MR or TR cells, respectively, and P<0.0001 P = 0.0007 because Rb was suppressed by Myc activity or T antigen binding in the 6.
tug.00 df-646 9 t=3.61 d-f-48 MR or TR MEFs, respectively. 43 '"4 We concluded that Bin) restrains anchorage-independent cell proliferation through a p53/Rb-independent 5-8 8 mechanism.
7-
Tumor formation experiments showed that Bin] loss similarly enhanced the transformed growth of MR MEFs in vivo. At a two week [4] [5] [6] endpoint, the mass of rumors formed in syngeneic hosts after s.c. injection S of MR MEFs was markedly greater for cells that lacked Bin), consistent
3-

4
with the effects of Bin) loss on in vitro proliferation (Fig. 3A) . The 53negative impact ofBin expression on tumor growth was less pronounced 2 , P in nude mouse hosts (data not shown), consistent with the finding that 2 " __Binl loss can contribute to tumorigenicity in a cell extrinsic manner 1--(Muller et al, manuscript in preparation). Interestingly, the benefit of 0 Binl loss to tumor formation was not replicated in TR MEFs, and 0indeed, loss of Bin) markedly limited tumor outgrowth in syngeneic mice 4'/"
4" 4'"
' (Fig.  3A) . This observation indicates that the effects of Bin) loss on c-myc-mediated tumor formation are specific. In addition, it suggests that MR MEF 6 Bin) loss may confer an in vivo benefit to c-myc-mediated tumor formation
MR MEbeyond
anchorage-independent proliferation, because TR MEFs gained labeled transferrin (Fig. 4A) , as was observed previously in untransformed MR + primary cells. 16 An additional finding that may relate to this issue was that
I-MR 4-• TR 4-
Binl loss increased the sensitivity of cells to paditaxel (Fig. 4B) , a drug that disrupts microtubule dynamics required for endocytoric trafficking. 47 Clonogenic growth assays confirmed that Bin) loss conferred sensitivity 3 -under conditions of long-term drug treatment (Fig. 5B) . We concluded that
• .
the effects of Bin) loss in MR MEFs produces an elevated sensitivity to microtubule disruption but not a generalized defect in endocytosis. anisms of apoptosis mediated by death receptor ligands such as tumor 0% 8 necrosis factor-a (TNF) have not been examined. Unfortunately, the p53 00, null MR MEFs generated in this study were not susceptibi t I TNF-induced cell death. Therefore, to examine this question we usedUEFs Ism transformed by the adenovirus E1A early region plus actvated H-ras 4a (termed ER MEFs or ER cells) that had been generated fr anothr study."15
0%
This relevance of this system is justified by fwsctiotnW similarity between 0% tronsferrin was documented by flow cytomotry 30 min after oddititon to MR We observed that Bin) delition in these cells ablated sensitivity to MEF cultures as described. 16 , 62 (B) Growth assay. SRB assay was performed TNF-induced apoptosis (Fig. 5A) . Western analysis of a set of key TNF 72 hr after exposure of cells in growth media to the concentration of podlisignaling proteins showed sim4ia expression of the TNF receptor-binding taxel indicated. (C) Clanageric assay. Relaom colony formation was determined adapter protein TRADV ad similar regulation of the NF-xB regulatory by crystal violet staining 13 days after treatment with 125 nM poclitaol of factor IiKB in each cel poptaan, however, downstream caspases and effector 4000 cells seeded overnight into a 100 mm dish. events including cleav of PARP and Bid and mitochondrial release of cytochrome C were actived only in the Binl)+* cells (Fig. 5B and 5C ). NF-iB actity is a key determinant of the TNF response. In electrophoretic DISCUSSION mobility shift 2says, we found that TNF stimulated NF-KB activity in both cell populations. However, Bin]" cells differed in their exhibition of a low This study offers the first direct evidence that the Bin)l basal level of precocious nuclear NF-KB activity (Fig. 50) . The stimulation Amphiphysin2 gene acts to restrain neoplastic cell growth. Previous of NF-iKB in both settings was consistent with the lack of a defect in IxB studies have found that Bin) expression is diminished in many cancers regulation, although it begged the question of how basal NF-KB activity was and that ectopic overexpression of nuclear-localizing Bin 1 splice increased in null cells. Nevertheless, since elevated NF-KB limits isoforms limits the proliferation or survival of malignant cells. Here TNF-induced cell death, we confirmed the expectation that cycloheximide the use of nullizygous mouse cells1 6 allowed the direct demonstration (CX) cotreatment could restore TNF sensitivity by ablating NF-KB (Fig. 6) . that Bin) suppresses the anchorage-independent growth, tumori-CX is used to sensitize primary MEFs to TNE Earlier studies suggested that genicity, and apoptotic susceptibility of neoplastically transformed Bin) was more likely to be involved in EIA-mediated sensitization to TNF gentyr rather than to be required for TNF-induced cell death. This expectation was Thisw met by the lack of an effect of Binl deletion on the ability of TNF+CX to This work address an hypothesized role for Bin] in restraining kill primary MEFs (Fig. 6) . In summary, the results support the concept of the oncogenicity of c-myc, focusing on p53-independent mechaa modifier role for Bin) in shaping the response of ER cells to an extrinsic nisms of restraint. This focus is justified by a need to address existing cell death signal.
gaps in knowledge concerning the identity of functions that can influence cell growth or survival in primary rodent or avian cells or in nonmalignant human cells. ' 3 " 4 6 The evidence that the inhibitoSry effects of Bin) are selective for a defining feature of cancer patho-0/I LL •physiology (anchorage-independent growth) argues strongly for a (cylusos) NFcB > negative modifier role rather than a generalized suppressor role (i.e., a gene that can restrain cell proliferation generally during neoplastic development, e.g., Rb). The results of tumor formation experiments offer additional sup- Figure 5 . Effect of Bini1 on TNF-inducecd cell death in E 1A+ras-transformed port for the conclusion that Bin) negatively modifies the oncogeniccells is associated with altered NF-KB activity. (A) Morphology and flow cytometry. ER MEFs in growth media were incubated 24 hr with 100 ng/ml ity of c-myc in cancer. While both MR and TR cells benefitted from TNF-a before being photomicrogrophy and processing for flow cytometry Bin) loss in terms of anchorage-independent growth, only MR cells (insets). (B) Western analyis. Cell extracts were prepared at the times indicated benefitted in terms of tumor formation. Bin) loss did not benefit following exposure to 100 ng/ml TNF-a before processing for Western tumor formation by TR MEFs (this study) or ER MEFs. 15 Thus, it blotting. (C). Cytochrome c release. Cell extracts were prepared and cytoso-is evident that Bin) has a selective effect in the context of oncogenic lic fractions were processed for Western blotting 8 hr after cell treatment transformation mediated by c-myc that is not shared with the viral with 100 ng/ml TNF-a. branes. 17 46 Genetic experiments in mice, fruit flies, and fission significant clinical interest in molecular markers of taxane sensitivity, which remain largely unknown. 55 Lastly, in light of the effects of The last aspect of this work examined a role for Bn in ined. 
Results
We used standard methods to generate a conditionally targeted ('floxed') allele of the murine Bin]
gene, except that a variant loxP site was incorporated at the most distal position in the targeting vector. Briefly, the targeting vector was constructed in which a neomycin resistance gene (neo) cassette flanked by wild-type loxP sites was inserted into 129sv genomic DNA spanning introns 2-5 of the mouse Bin] gene(9) (Fig. 1) . Approximately I kb downstream of the neo casette a variant loxP site incorporating a T->C transition at position 7 was inserted, such that exon 3 was flanked on its 5' side by a wild-type loxP site and on its 3' side by the variant loxP site (Fig. 1) . This point mutation is reported to decrease the binding affinity of one Cre recombinase monomer for the loxP half site by -30-fold(4). ES cell clones produced by electroporation of the targeting plasmid and G418 selection were screened for homologous recombination by PCR using primers located within the neo gene and the flanking regions (as indicated by thin arrows in Figure 1 ). In one clone, Cre was expressed transiently by electroporation of the expression vector pOG231 (11, 12) . PCR analysis of 30 colonies generated by limiting dilution of the electroporated cells was performed.
Eight colonies exhibited deletion of the neomycin marker cassette and 3/8 of these colonies (38%) Subsequent analysis of mice generated from the targeted ES cells demonstrated that the variant loxP site was able to support Cre-mediated recombination in vivo. Briefly, standard methods were used for ES cell injection into blastocysts and implantation resulting in the production of two germline chimeric mice (data not shown). Each mouse harbored the desired floxed exon 3 allele (Fig. 1) , the structure of which was confirmed by PCR and DNA sequencing (data not shown).
Tissue-specific excision was confirmed by examining the structure of the floxed BinI allele in female offspring generated from crosses to WAP-Cre transgenic animals. The whey acidic protein (Wap) promoter is used commonly to target gene expression specifically to the mammary gland epithelium (16) . Recombination in Wap-Cre transgenic mice is largely restricted to the mammary gland with occasional recombination occurring in the brain (16) . Homogeneous high level expression from the Wap promoter is confined to the lactational stage of pregnancy, although transient expression is also observed during the estrus cycle (14) . In the conditional flox Bin] knockout mice created, PCR analysis revealed no evidence of recombination in the mammary gland of virgin females (data not shown), where the wap promoter is inactive, but evidence of recombination in the mammary gland of nursing females where activation of the wap promoter drives Cre expression ( Fig. 2A) . Recombination in mammary gland tissue was detected from late pregnancy through weaning, although by full regression stage after weaning the product of the recombined allele was faint due to loss of epithelial cells caused by involution (Fig. 2B) . In summary, use of the variant loxP site facilitates the ability to obtain an ES cell population with the desired flox allele without abrogating the in vivo competency of the allele to be targeted in a tissue-specific manner by Cre recombinase.
Systemic deletion produces an embryonic or perinatal lethal phenotype for many genes including recombination of loxP-flanked alleles has been reported to produce complete systemic deletion in 50% of the progeny produced with the remaining 50% of the progeny being mosaics (6) . Using the variant 3' loxP site, we observed a frequency of 6% complete systemic recombinants, 60% mosaic animals, and 34% non-recombinants (Table I and Fig. 4) . These results provide a measure of the competency of the flox allele to be targeted by Cre in vivo. We also found observed that, while the frequency of recombination varied between individual mosaic mice, as would be expected, the proportion of recombined to non-recombined alleles was consistent across all tissues examined from each mouse (Fig. 5) . We concluded that use of the variant 3' loxP site did not compromise in vivo recombination and was useful for more efficient production of mosaic animals.
Discussion
This report describes a simple strategy to promote partial Cre-mediated recombination within a 'tri-lox' allele to achieve specific excision of a floxed DNA region. This method addresses a common barrier to the production of conditional knockout mice, where one wishes to remove a dominant selectable marker from a gene targeting construct that has been integrated homologously into the genome of an ES cell line. This strategy, which is generalizable to any 'tri-lox' design where an intermediate recombination step is desired, is based in an apparent difference in the efficiency by which Cre recognizes and/or mediates recombination from a mutated loxP site in vitro versus in vivo. While it is possible to design strategies using both FLP and Cre recombinases to achieve distinct step-wise deletions in a targeting construct (15) cells. Assuming a mean representation of 50% recombined and 50% non-recombined alleles, the use of mosaic animals can double the power of the analysis for each mouse that is evaluated. Thus the number of mice needed to obtain statistically relevant data can be significantly reduced.
Selecting a population of mice with a lower proportion of recombined alleles will make the analysis more stringent, while selecting for a higher proportion will make it less so. Since the proportion of recombined to non-recombined alleles can be predicted for internal organs from PCR analysis of a standard tail biopsy, identifying the desired population to study is technically straightforward. Third, mosaic analysis is particularly useful in a mixed genetic background, as the paired control is derived from the same animal rather than from a different littermate with a different distribution of parental alleles. Fourth, Cre expression is restricted to very early embryogenesis, alleviating the concern that contemporaneous Cre recombinase activity may influence the phenotype (a common issue in tissue-specific knockouts). Lastly, the mosaic model allows one to gauge the impact of field effects by allowing one to vary the extent of gene loss in a The development of conditional mouse knockout mice has become an essential technology for basic research aimed at determining gene function in the in vivo context as well as for pre-clinical target validation studies. This study provides a strategy to overcome a major technical challenge to the production of conditional knockout mice, and it shows how this strategy can be applied not only to the production of standard tissue-targeted knockouts, but also to facilitating the production of mosaic knockouts, which have a number of distinct advantages for studies of tumorigenesis and other pathophysiological processes.
Materials and Methods
Production of embryonic stem cell lines and germline chimeric mice. Using standard methods, a targeting plasmid with the structure presented in Figure 1 was electroporated into embryonic stem (ES) cells derived from 129sv mice and cell clones were identified by G418 selection. Three clones which integrated the plasmid by homologous recombination were defined by PCR analysis and the structure of the desired targeting event was confirmed by DNA sequencing. These ES cell lines were subsequently electroporated with the Cre vector pOG231 (11, 12) and subcloned by limiting dilution to identify colonies in which selective excision of the neo marker had occurred.
Of 30 colonies analyzed 8/30 sustained deletion of the neo marker gene and 3/8 of the recombined clones retained the floxed exon 3 segment (Fig. 1) . Two ES subclones were microinjected into C57BL/6J blastocysts and two highly chimeric animals exhibiting germline transmission of the 
